NOT-CA-20-057: Notice of Change to the First Receipt Date of RFA-CA-20-027 and RFA-CA-20-028, "Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01/R21 Clinical Trial Optional)"

Notice of Change to the First Receipt Date of RFA-CA-20-027 and RFA-CA-20-028, "Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01/R21 Clinical Trial Optional)"

Notice Number: NOT-CA-20-057

Key Dates
Release Date: April 28, 2020

Related Announcements

RFA-CA-20-027 Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01 Clinical Trial Optional)

RFA-CA-20-028 Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R21 Clinical Trial Optional)

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to revise the "key dates" for RFA-CA-20-027, and RFA-CA-20-028 Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01/R21 Clinical Trial Optional)". This new receipt date will allow applicants more time to prepare applications given the delays and complications caused by the COVID-19 pandemic.

In Part 1 of both RFAs, under Key Dates, the first Application Due Date now has a revised due date of October 1, 2020; "Scientific Merit Review" now has a revised date of January 2021; "Advisory Council Review" now has a revised date of May 2021; and "Earliest Start Date" has a revised date of July 2021.

I. Part 1 Key Dates in RFA-CA-20-027 and RFA-CA-20-028
Currently Reads:

Application Due Date(s)
July 31, 2020; July 30, 2021

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Scientific Merit Review
October/November 2020; October/November 2021

Advisory Council Review
January 2021; January 2022

Earliest Start Date
April 2021; April 2022

II. Part 1 Key Dates in RFA-CA-20-027 and RFA-CA-20-028
Modified (by this Notice) to Read (in italics):

Application Due Date(s)
October 1, 2020; July 30, 2021

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Scientific Merit Review
January 2021; October/November 2021

Advisory Council Review
May 2021; January 2022

Earliest Start Date
July 2021; April 2022

III. Part 1 Key Dates in RFA-CA-20-027 and RFA-CA-20-28 Remain Unmodified:

Letter of Intent Due Date(s)
30 days prior to the application due date

Expiration Date
July 31, 2021

NOTE: All other aspects of these funding opportunity announcements (RFA-CA-20-027 and RFA-CA-20-028) remain unchanged.

Inquiries

Please direct all inquiries to:

Michelle Mollica, Ph.D., M.P.H., R.N., O.C.N.,
Healthcare Delivery Research Program
National Cancer Institute (NCI)
Telephone: 240-276-7621
Email: [email protected]

Danielle Daee, Ph.D.,
Epidemiology and Genomics Research Program
National Cancer Institute (NCI)
Telephone: 240-276-5744
Email:[email protected]